Here, we demonstrate a further improvement of the NYS CF NBS algorithm, with the implementation of a new CFTR molecular assay utilizing NGS technology that includes a customizable second-tier panel and combines second- and third-tier testing onto a single platform, streamlining workflows. The gene discussed is CFTR; the disease is cystic fibrosis.